Enrollment for the program will begin in the first quarter of 2008 with an expected completion date in the second half of the year.
CP404 is a calcium channel blocker used in a nasal formulation to block olfactory activity and alter behavior to reduce food intake. Compellis Pharmaceuticals has tested a series of like compounds and believes the effect can be seen in the overall class of calcium channel blockers. The advantage of CP404 is that it is a small molecule that is well tolerated in man and is readily manufactured.
Christopher Adams, CEO of Compellis, said: “The investigational new drug (IND) application approval is a significant milestone achievement for the Compellis/Pennington obesity therapy development effort. Principal investigator Frank Greenway has significant experience with the clinical development of obesity and nutritional therapies. We are excited about entering the Phase I study and look forward to the clinical results of CP404.”